Participants 13 37 4
monoethylglycinexylidide
Participants 44 96 4
assessment of liver function with fewer side effects
Participants 379 462 4
subjects with normal (n = 5) and severely impaired liver function (n = 7) (study I)
Participants 1441 1445 3
dose
Participants 1584 1641 3
individuals with more severely compromised liver function
